MY193625A - Probiotic composition for treatment or prevention of high blood cholesterol - Google Patents

Probiotic composition for treatment or prevention of high blood cholesterol

Info

Publication number
MY193625A
MY193625A MYPI2015702828A MYPI2015702828A MY193625A MY 193625 A MY193625 A MY 193625A MY PI2015702828 A MYPI2015702828 A MY PI2015702828A MY PI2015702828 A MYPI2015702828 A MY PI2015702828A MY 193625 A MY193625 A MY 193625A
Authority
MY
Malaysia
Prior art keywords
prevention
treatment
high blood
blood cholesterol
probiotic composition
Prior art date
Application number
MYPI2015702828A
Inventor
Min Tze Liong
Lee Ching Lew
Huey Shi Lye
Joo Ann Ewe
Nazalan Mohd Najimudin MOHD
Kee Shin Sim
Li Onn Chuah
Sy Bing Choi
Ohno Hiroshi
Original Assignee
Univ Sains Malaysia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Sains Malaysia filed Critical Univ Sains Malaysia
Priority to MYPI2015702828A priority Critical patent/MY193625A/en
Priority to PCT/MY2016/050015 priority patent/WO2017034389A1/en
Publication of MY193625A publication Critical patent/MY193625A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

A composition capable of reducing total serum cholesterol in a subject upon ingestion comprising Lactobacillus fermentum strain FTDC 8312 in a pharmaceutically effective amount. (No illustrations for abstract)
MYPI2015702828A 2015-08-25 2015-08-25 Probiotic composition for treatment or prevention of high blood cholesterol MY193625A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
MYPI2015702828A MY193625A (en) 2015-08-25 2015-08-25 Probiotic composition for treatment or prevention of high blood cholesterol
PCT/MY2016/050015 WO2017034389A1 (en) 2015-08-25 2016-03-17 Probiotic composition for treatment or prevention of high blood cholesterol

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MYPI2015702828A MY193625A (en) 2015-08-25 2015-08-25 Probiotic composition for treatment or prevention of high blood cholesterol

Publications (1)

Publication Number Publication Date
MY193625A true MY193625A (en) 2022-10-20

Family

ID=58100398

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2015702828A MY193625A (en) 2015-08-25 2015-08-25 Probiotic composition for treatment or prevention of high blood cholesterol

Country Status (2)

Country Link
MY (1) MY193625A (en)
WO (1) WO2017034389A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112877241B (en) * 2021-02-02 2022-02-11 浙江大学 Human lactobacillus fermentum ZJUIDS06 and application thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR101600A0 (en) * 2000-10-25 2000-11-16 Atheromastat Pty Ltd Compositions and methods for diagnosis and treatment of cardiovascular disorders

Also Published As

Publication number Publication date
WO2017034389A1 (en) 2017-03-02

Similar Documents

Publication Publication Date Title
PH12017501342A1 (en) Glycan therapeutics and related methods thereof
WO2016086209A8 (en) Probiotic and prebiotic compositions, and methods of use thereof for treatment of gastrointestinal disorders
MY186217A (en) Mixture of hmos
SG10201907660YA (en) Use of short chain fatty acids in cancer prevention
WO2015047941A3 (en) Compositions and methods for treatment and prophylaxis of gastrointestinal diseases
MX2022011742A (en) Nutritional composition for gastrointestinal environment to provide improved microbiome and metabolic profile.
MX2018002543A (en) Compositions comprising urolithin compounds.
EP4086335A4 (en) Lactobacillus fermentum strain, and composition for preventing or treating metabolic diseases, comprising same
EP4086334A4 (en) Lactobacillus fermentum strain, and composition for preventing or treating metabolic diseases containing same
MX2017007654A (en) Probiotic strains having cholesterol absorbing capacity, methods and uses thereof.
PH12017502042A1 (en) Dietary supplement
PH12018550110A1 (en) Novel probiotic bacterial strain of lactobacillus plantarum and compositions and uses thereof in the treatment of inflammation
MX2017015702A (en) Pharmaceutical and food compositions for inducing satiation and prolonging satiety in subjects in need thereof.
WO2020091179A3 (en) Composition for preventing or treating secondary osteoporosis comprising probiotics as active ingredient
WO2015121458A3 (en) Use of compositions comprising bifidobacterium animalis ssp. lactis lmg p-28149
PH12019501439A1 (en) Use of lactic acid bacteria to treat or prevent gestational diabetes mellitus
WO2014011564A3 (en) Compositions and method for treatment and prophylaxis of inflammatory bowel disease
WO2020091180A3 (en) Composition for preventing or treating secondary osteoporosis comprising probiotics as active ingredient
MX2017007969A (en) Lactic acid bacteria and their use for the treatment of mastitis.
MX370436B (en) Pharmaceutical composition for use in the treatment or prevention of vitamin and mineral deficiencies in patients which have been subjected to gastric bypass-surgery.
MY193625A (en) Probiotic composition for treatment or prevention of high blood cholesterol
MX2021010219A (en) Composition for use in the prevention and/or treatment of dysbiosis.
JP2016003187A5 (en)
MX2020013860A (en) Lactobacillus plantarum compositions and uses thereof.
MX2020007906A (en) Composition comprising new lactobacillus salivarius strains and method for the prevention and treatment of otitis and upper respiratory infections.